Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
PCI Biotech AS - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'PCI Biotech AS - Product Pipeline Review - 2014', provides an overview of the PCI Biotech AS's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of PCI Biotech AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of PCI Biotech AS including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of PCI Biotech AS's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the PCI Biotech AS's pipeline products Reasons to buy - Evaluate PCI Biotech AS's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of PCI Biotech AS in its therapy areas of focus - Identify new drug targets and therapeutic classes in the PCI Biotech AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of PCI Biotech AS and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of PCI Biotech AS - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of PCI Biotech AS and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 PCI Biotech AS Snapshot 5 PCI Biotech AS Overview 5 Key Information 5 Key Facts 5 PCI Biotech AS - Research and Development Overview 6 Key Therapeutic Areas 6 PCI Biotech AS - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 PCI Biotech AS - Pipeline Products Glance 11 PCI Biotech AS - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 PCI Biotech AS - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 PCI Biotech AS - Drug Profiles 14 bleomycin sulfate 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 gemcitabine hydrochloride 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 (TPCS2a + ADC) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 (TPCS2a + siRNA) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 TPCS-2A 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PCI Biotech AS - Pipeline Analysis 21 PCI Biotech AS - Pipeline Products by Target 21 PCI Biotech AS - Pipeline Products by Route of Administration 22 PCI Biotech AS - Pipeline Products by Molecule Type 23 PCI Biotech AS - Pipeline Products by Mechanism of Action 24 PCI Biotech AS - Recent Pipeline Updates 25 PCI Biotech AS - Dormant Projects 27 PCI Biotech AS - Discontinued Pipeline Products 28 Discontinued Pipeline Product Profiles 28 (amphinex + epirubicin hydrochloride) 28 PCI Biotech AS - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables PCI Biotech AS, Key Information 5 PCI Biotech AS, Key Facts 5 PCI Biotech AS - Pipeline by Indication, 2014 7 PCI Biotech AS - Pipeline by Stage of Development, 2014 8 PCI Biotech AS - Monotherapy Products in Pipeline, 2014 9 PCI Biotech AS - Combination Treatment Modalities in Pipeline, 2014 10 PCI Biotech AS - Phase II, 2014 11 PCI Biotech AS - Phase I, 2014 12 PCI Biotech AS - Preclinical, 2014 13 PCI Biotech AS - Pipeline by Target, 2014 21 PCI Biotech AS - Pipeline by Route of Administration, 2014 22 PCI Biotech AS - Pipeline by Molecule Type, 2014 23 PCI Biotech AS - Pipeline Products by Mechanism of Action, 2014 24 PCI Biotech AS - Recent Pipeline Updates, 2014 25 PCI Biotech AS - Dormant Developmental Projects,2014 27 PCI Biotech AS - Discontinued Pipeline Products, 2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.